Epizyme (EPZM) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
May 10, 2022 7:00 AM EDTTAZVERIK® (tazemetostat) Net Product Revenue of $8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021
First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epizymes Phase 1b/3 Confirmatory Study Assessing Tazemetostat in Combination with R2 in Follicular Lymphoma (FL)
Updated Data from the Phase 1b Portion of SYMPHONY-1 to be Presented at ASCO; Additional Updates Anticipated in 2H 2022 from Tazemetostat and EZM0414 (SETD2 inhibitor) Studies
CAMBRIDGE, Mass.--(BUSINESS... More
